JUN 1 2 2006 W

## IAP15 Rec'd PCT/PTO 12 JUN 2006

10/582496

## THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. :

PCT/EP2004/012764

International Filing Date

November 11, 2004

Priority Date(s) Claimed

December 10, 2003

Applicant(s) (DO/EO/US)

Dirk FINSINGER et al.

Title: DIACYLHYDRAINE DERIVATIVES

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

## Timing and Fees

$\boxtimes$	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this infor disclosure statement is filed:						
		within three months of the filing date of a national application other than a CPA under § 1.53(d);					
	$\boxtimes$	within three months of the actual filing date of the national phase of a PCT application; OR					
		before the mailing of a first substantive office action (including after filing of an RCE).					
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ed in 37 C.F.R. § 1.97(b), but before the mailing date of:					
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and					

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a ı	notice of allowance under 37 C.F.R. § 1.311;
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$	-	s of materials listed but not attached were cited in an international search dated March 3, 2005.
		Not re	quired by 37 CFR § 1.98.
		Copies	s of the materials listed are attached (except for the foregoing).

Non-E	nglish l	Language References						
	$\boxtimes$	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).						
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:						
		<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> </ul>						
		A = document defining the general state of the art						
		O = non-written disclosure						
		<ul> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the</li> </ul>						
		invention						
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date						
		D = cited in the application						
		L = cited for another reason						
		& = publication of member of same patent family						
		Translation of other relevant information on foreign search report						
		[insert necessary translation here]						
Other	Informa	<u>ation</u>						
Payme	ent of Fe	ees Due (If Any):						
	A chec	ck for \$ covering the fee identified above is attached.						
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.						

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3171

Date: June 12, 2006

AJZ:aap

K:\Merck\3000 - 3999\3171\Information Disclosure Statement.doc

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTO		<u>-</u>	Complete if Known		
				Application Number	Unassigned	
INFO	RMATION	DIS	CLOSURE	Filing Date	June 12, 2006	
STAT	EMENT BY	Y AP	PLICANT	First Named Inventor	Dirk FINSINGER et al.	
				Group Art Unit	Unassigned	
	(use as many she	ets as r	necessary)	Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	MERCK-3171	

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.¹	U.S. Patent Docum	ment Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY	
	1	5354762			October 11, 1994	
	2	2003207914			November 6, 2003	
	3	2001011136			August 2, 2001	

				FORE	IGN PATENT DOCUMEN	NTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Kind Code <sup>5</sup> Office <sup>3</sup> Number <sup>4</sup> (if known)		Kind Code <sup>5</sup> Name of Patentee or Applicant of Date of Publication of Cited		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
	5	wo	2004085399		Merck Patent GmbH	October 7, 2004		
	6	wo	2004037789		Merck Patent GmbH	May 6, 2004		
	7	wo	2004019941		Merck Patent GmbH	March 11, 2004		
	8	EP	0253468		Rohm and Haas Company	January 20, 1998		Equv to cite 1
	9	wo	02085857		Bayer Corporation	October 31, 2002		Equv to cite 2
	10	wo	9324468		CIBA-GEIGY AG	December 9, 1993		
	11	wo	03037864		Japan Tobacco Inc.	May 8, 2003		
	12	wo	0042012		Bayer Corporation	July 20, 2000		Equv to cite 3

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute fo	or form 1449A/PT	0		Complete if Known		
INFOF	NA A TION	DIO.		Application Number	Unassigned	
			CLOSURE	Filing Date	June 12, 2006	
STATI	EMENT B	Y AF	PPLICANT	First Named Inventor	Dirk FINSINGER et al.	
				Group Art Unit	Unassigned	
(1	ise as many sh	eets as	necessary)	Examiner Name	Unassigned	
Sheet 2 of 2				Attorney Docket Number	MERCK-3171	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	13	SMITH R A ET AL: "DISCOVERY OF HETEROCYCLIC UREAS AS A NEW CLASS OF RAF KINASE INHIBITORS: IDENTIFICATION OF A SECOND GENERATION LEAD BY A COMBINATORIAL CHEMISTRY APPORACH" BIOORGANIC & MEDICNAL CHEMISTRY LETTERS, OXFORD, GB vol. 11, no. 20, 2001, pages 2775-2778, XP001118699					
	14	JOSHI, NAILESH ET AL: "ARYLAMIDES. PARTS V: N'-P-(2,4-DIMETHYOXY-S-TRIAZIN-6-YLAMINOBE NOZOYL)-N2-SUBSTITUTED BENZOYL HYDRAZINES" JOURNAL OF THE INSTITUTION OF CHEMISTS (INDIA), 64(3), 105-6 CODEN: JOICA7; ISSN: 0020-3254, 1992, XP009044479					
	<del></del>						

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.